A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.

Koti, Madhuri; Robert Siemens, D

Koti, Madhuri; Robert Siemens, D.

Afiliação

Koti M; Department of Biomedical and Molecular Sciences, Department of Urology, Cancer Research Institute, Queen's University, Kingston, ON, Canada. Electronic address: kotim@queensu.ca.
Robert Siemens D; Department of Biomedical and Molecular Sciences, Department of Urology, Cancer Research Institute, Queen's University, Kingston, ON, Canada.

Eur Urol ; 84(5): 447-448, 2023 11.

Article em En | MEDLINE | ID: mdl-37400353

ABSTRACT

ABSTRACT

Treatment-naïve tumors from patients who then experience recurrence or progression after bacillus Calmette-Guérin (BCG) therapy exhibit elevated expression of genes associated with basal differentiation and immune suppression. Three tumor molecular subtypes have been associates with distinct clinical outcomes and will allow early identification of patients unlikely to respond to BCG immunotherapy.

Assuntos

Neoplasias não Músculo Invasivas da Bexiga; Neoplasias da Bexiga Urinária; Humanos; Vacina BCG/uso terapêutico; Adjuvantes Imunológicos/uso terapêutico; Recidiva Local de Neoplasia/tratamento farmacológico; Imunoterapia/efeitos adversos; Neoplasias da Bexiga Urinária/tratamento farmacológico; Neoplasias da Bexiga Urinária/genética; Administração Intravesical; Invasividade Neoplásica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Neoplasias não Músculo Invasivas da Bexiga Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google